BioTrinity is Europe’s leading investment and bio-partnering conference and provides a unique platform for companies across the life sciences industry to achieve their business objectives, secure...
Coronary heart disease (CHD) is the leading cause of death both in the UK and worldwide. CHD generally affects more men than women, but both are at higher risk as age increases. The disease occurs...
Two big things struck me as interesting during an Innovations in Oncology Conference in Edinburgh this month. Firstly how exciting the market is right now, with many productive collaborations...
There’s no common worldwide definition of what constitutes a rare disease. The European Commission on Public Health defines rare diseases as "life-threatening or chronically debilitating diseases...
Fabry disease is caused by a mutation in the alpha-galactosidase-A gene (GLA). This gene codes for an enzyme active in lysosomes, the recycling centres within cells. Lysosomes contain more than 50...
Speciality pharma firm Shire has agreed to buy Baxalta for around $32 billion (£22 billion), to further expand its portfolio of treatments for rare diseases. Baxalta, the spun-off pharmaceutical...
Black Swan Analysis has just been short-listed for the “The Management Team of the Year Award” sponsored by NatWest and open to outstanding management teams in the Thames Valley. We are joined on the...
Black Swan Analysis has been shortlisted for the Micro Business of the Year category, for this year’s Growing Business Awards, in association with Lloyds Bank, supported by Real Business and the CBI....
Although Sickle Cell Disease (SCD) is the most frequent haemoglobinopathy worldwide, it remains a rare blood disorder in most western countries. Globally, an estimated 5% of the world’s population...
